Table 5. West Nile virus records in equids in Africa (period 1975–2015).
Country | Year of the study | Viral Isolation | Antibody detection | Seroprevalence rate | References |
---|---|---|---|---|---|
Algeria | 1975 | - | + | 96.6% | [44e] |
Chad | 2003 | - | + | 97% | [78f,n] |
Djibouti | 2004–2005 | - | + | 9% | [78f,n] |
Democratic Republic of Congo | 2004 | - | + | 30% | [78f,n] |
Egypt | 1963 | - | + | 54% | [80g] |
Gabon | 2004 | - | + | 3% | [78f] |
Ivory Coast | 2003 | - | + | 79% | [81f] |
Ivory Coast | 2003–2004–2005 | - | + | 28% | [78f] |
Morocco | 1996 (42 deaths) | + | - | - | [7b] |
Morocco | After the epizootic of 1996 | - | + | 42–57% | [82e] |
Morocco | 2003 (5 deaths) | + | - | - | [83f] |
Morocco | 2010 (8 deaths) | + | - | - | [44f] |
Morocco | 2011 | - | + | 31% | [84f,g] |
Morocco | 2018 | - | + | 33.7% | [42f,h,m] |
Nigeria | 2011–2012 | - | + | 90.3% | [85f,i] |
Nigeria | 2014 | - | + | 11.5% | [86g] |
Nigeria | 2014 | - | + | 8.5% (donkeys) | [86g] |
Senegal | 2002–2003, Dakar | - | + | 92% | [78f,l] |
Senegal | 2003, Ferlo area | - | + | 78.3% | [61l] |
Senegal | 2005, Senegal river basin | - | + | 85% | [87f,g] |
Senegal | 2014, North-west Senegal | - | + | 68.7% | [88f] |
Senegal | 2014, Keur Momar Sarr | - | + | 86.2% | [88f] |
South Africa | 2001 | - | + | 15% (foals) | [89l] |
South Africa | 2001 | - | + | 11% (yearlings) | [89l] |
South Africa | 2001 | - | + | 75% (dams) | [89l] |
South Africa | 2007–2008 | - | + | 21.8% | [13f,g] |
South Africa | 2008–2015 | - | + | 7.4% | [79f,g] |
Tunisia | 1980 | - | + | 0.35% | [90e] |
Tunisia | 2005 | - | + | 25% | [91e] |
Tunisia | 2005 | - | + | 37% (donkeys & mules) | [91e] |
Tunisia | 2007 | - | + | IgG 30% | [92f] |
Tunisia | 2007 | - | + | IgM 0.78% | [92f] |
Tunisia | 2008 | - | + | 27.1% | [93f] |
+ At least one study report with positive results found;—no available studies; () specified when not horses
a = “virus isolation on cell cultures / injection into suckling mice. Viruses detected by immunofluorescence assay using specific mouse immune ascitic fluids”
b = “RNA molecular detection”
c = “viral isolation, not specified if a and/or b”; antibodies detection via
d = “hemagglutination-inhibition test (HIT)”
e = “serological surveys, type of antibodies detection tests non specified”
f = “epitope-blocking enzyme-linked immunosorbent assay (ELISA)”
g = “virus-neutralization test (VNT)”
h = “micro virus-neutralization test (micro-VNT)”
i = “immunoglobulin M (IgM)-specific ELISA”
l = “plaque reduction neutralization test (PRNT)”
m = “flavivirus microsphere immunoassay (MIA)”
n = “immunoblotting method (WB).”